Tracing the substrate translocation mechanism in P-glycoprotein

P-glycoprotein (Pgp) is a prototypical ABC transporter of great biological and clinical significance that confers cancer multidrug resistance and mediates the bioavailability and pharmacokinetics of many drugs1–3. Decades of structural and biochemical studies have provided insights into how Pgp binds diverse compounds4–9, but how they are translocated through the membrane has remained elusive. Here, we covalently attached a cyclic substrate to discrete sites of Pgp and determined multiple complex structures in inward- and outward-facing states by cryoEM. In conjunction with molecular dynamics simulations, our structures trace the substrate passage across the membrane and identify conformational changes in transmembrane helix 1 (TM1) as regulators of substrate transport. In mid-transport conformations, TM1 breaks at glycine 72. Mutation of this residue significantly impairs drug transport of Pgp in vivo, corroborating the importance of its regulatory role. Importantly, our data suggest that the cyclic substrate can exit Pgp without the requirement of a wide-open outward-facing conformation, diverting from the common efflux model for Pgp and other ABC exporters. The substrate transport mechanism of Pgp revealed here pinpoints critical targets for future drug discovery studies of this medically relevant system.

[1]  J. Kowal,et al.  Cryo-EM structures reveal distinct mechanisms of inhibition of the human multidrug transporter ABCB1 , 2020, Proceedings of the National Academy of Sciences.

[2]  E. Lindahl,et al.  Heterogeneous Parallelization and Acceleration of Molecular Dynamics Simulations in GROMACS , 2020, The Journal of chemical physics.

[3]  David J. Fleet,et al.  Non-uniform refinement: adaptive regularization improves single-particle cryo-EM reconstruction , 2019, Nature Methods.

[4]  R. Read,et al.  Improvement of cryo-EM maps by density modification , 2019, Nature Methods.

[5]  Tristan Bepler,et al.  Topaz-Denoise: general deep denoising models for cryoEM and cryoET , 2019, Nature Communications.

[6]  J. Kowal,et al.  Structural insight into substrate and inhibitor discrimination by human P-glycoprotein , 2019, Science.

[7]  D. Januliene,et al.  Know your detergents: A case study on detergent background in negative stain electron microscopy. , 2018, Journal of structural biology.

[8]  Randy J Read,et al.  Real-space refinement in PHENIX for cryo-EM and crystallography , 2018, bioRxiv.

[9]  Conrad C. Huang,et al.  UCSF ChimeraX: Meeting modern challenges in visualization and analysis , 2018, Protein science : a publication of the Protein Society.

[10]  I. Urbatsch,et al.  Substrate-induced conformational changes in the nucleotide-binding domains of lipid bilayer–associated P-glycoprotein during ATP hydrolysis , 2017, The Journal of Biological Chemistry.

[11]  David J. Fleet,et al.  cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination , 2017, Nature Methods.

[12]  B. L. de Groot,et al.  CHARMM36m: an improved force field for folded and intrinsically disordered proteins , 2016, Nature Methods.

[13]  Alexander D. MacKerell,et al.  CHARMM-GUI Input Generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM Simulations Using the CHARMM36 Additive Force Field , 2015, Journal of chemical theory and computation.

[14]  Berk Hess,et al.  GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers , 2015 .

[15]  Sunhwan Jo,et al.  CHARMM‐GUI Membrane Builder toward realistic biological membrane simulations , 2014, J. Comput. Chem..

[16]  Marcus A. Brubaker,et al.  Alignment of cryo-EM movies of individual particles by optimization of image translations. , 2014, Journal of structural biology.

[17]  I. Urbatsch,et al.  Directed evolution of P-glycoprotein cysteines reveals site-specific, non-conservative substitutions that preserve multidrug resistance , 2014, Bioscience reports.

[18]  P. Borst,et al.  P-glycoprotein ABCB1: a major player in drug handling by mammals. , 2013, The Journal of clinical investigation.

[19]  K. Brouwer,et al.  In Vitro Methods to Support Transporter Evaluation in Drug Discovery and Development , 2013, Clinical pharmacology and therapeutics.

[20]  Sjors H.W. Scheres,et al.  RELION: Implementation of a Bayesian approach to cryo-EM structure determination , 2012, Journal of structural biology.

[21]  Alexander D. MacKerell,et al.  Automation of the CHARMM General Force Field (CGenFF) II: Assignment of Bonded Parameters and Partial Atomic Charges , 2012, J. Chem. Inf. Model..

[22]  Alexander D. MacKerell,et al.  Automation of the CHARMM General Force Field (CGenFF) I: Bond Perception and Atom Typing , 2012, J. Chem. Inf. Model..

[23]  Antonín Pavelka,et al.  CAVER 3.0: A Tool for the Analysis of Transport Pathways in Dynamic Protein Structures , 2012, PLoS Comput. Biol..

[24]  G. Chang,et al.  A Gene Optimization Strategy that Enhances Production of Fully Functional P-Glycoprotein in Pichia pastoris , 2011, PloS one.

[25]  Jan H. Jensen,et al.  Improved Treatment of Ligands and Coupling Effects in Empirical Calculation and Rationalization of pKa Values. , 2011, Journal of chemical theory and computation.

[26]  Jan H. Jensen,et al.  PROPKA3: Consistent Treatment of Internal and Surface Residues in Empirical pKa Predictions. , 2011, Journal of chemical theory and computation.

[27]  Vincent B. Chen,et al.  Correspondence e-mail: , 2000 .

[28]  D. Clarke,et al.  Identification of Residues in the Drug Translocation Pathway of the Human Multidrug Resistance P-glycoprotein by Arginine Mutagenesis* , 2009, The Journal of Biological Chemistry.

[29]  Alexander D. MacKerell,et al.  CHARMM general force field: A force field for drug‐like molecules compatible with the CHARMM all‐atom additive biological force fields , 2009, J. Comput. Chem..

[30]  Yue Weng,et al.  Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding , 2009, Science.

[31]  M. Parrinello,et al.  Canonical sampling through velocity rescaling. , 2007, The Journal of chemical physics.

[32]  M. Gottesman,et al.  Targeting multidrug resistance in cancer , 2006, Nature Reviews Drug Discovery.

[33]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[34]  M. Fromm,et al.  Importance of P-glycoprotein at blood-tissue barriers. , 2004, Trends in pharmacological sciences.

[35]  A. Schinkel,et al.  P-Glycoprotein, a gatekeeper in the blood-brain barrier. , 1999, Advanced drug delivery reviews.

[36]  Berk Hess,et al.  LINCS: A linear constraint solver for molecular simulations , 1997, J. Comput. Chem..

[37]  B. Sankaran,et al.  P-glycoprotein Is Stably Inhibited by Vanadate-induced Trapping of Nucleotide at a Single Catalytic Site (*) , 1995, The Journal of Biological Chemistry.

[38]  J M Thornton,et al.  LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. , 1995, Protein engineering.

[39]  M C Willingham,et al.  Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[40]  M. Parrinello,et al.  Polymorphic transitions in single crystals: A new molecular dynamics method , 1981 .

[41]  S. Ambudkar,et al.  Molecular basis of the polyspecificity of P-glycoprotein (ABCB1): recent biochemical and structural studies. , 2015, Advances in cancer research.

[42]  I. Cascorbi P-glycoprotein: tissue distribution, substrates, and functional consequences of genetic variations. , 2011, Handbook of experimental pharmacology.